Gilead Finalizes $7.8B Arcellx Acquisition, Closes Ouro Medicines Deal
GILD sits 24% above its 52-week low of $104.46 on elevated volume (2.2× avg).
Summary
Gilead Sciences has finalized two significant acquisitions, completing the $7.8 billion purchase of Arcellx and closing the Ouro Medicines deal. The Arcellx acquisition, which adds a next-gen CAR-T therapy, was previously announced as completed in an April 28th 8-K, though at a slightly lower reported value. The Ouro Medicines deal, focused on inflammation therapeutics, was previously reported as a binding agreement in late March. These strategic moves confirm Gilead's pipeline expansion, with their financial impact, including substantial IPR&D charges, already factored into the company's revised full-year net loss outlook reported in its May 7th Q1 earnings.
At the time of this announcement, GILD was trading at $129.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $160.4B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.